Sodium Iodide → 6-[2-(4-Cyclobutylpiperazin-1-yl)-2-oxoethyl]-5,6,7,8-tetrahydro-pyrido[3,4-b]pyrazine

HRID 1713141Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1713141
[N:1]1[CH:6]=[CH:5][N:4]=[C:3]2[CH2:7][NH:8][CH2:9][CH2:10][C:2]=12.[Na+].[I-].C([O-])([O-])=O.[K+].[K+].Cl[CH2:20][C:21]([N:23]1[CH2:28][CH2:27][N:26]([CH:29]2[CH2:32][CH2:31][CH2:30]2)[CH2:25][CH2:24]1)=[O:22]>C(#N)C.C(Cl)Cl>[CH:29]1([N:26]2[CH2:27][CH2:28][N:23]([C:21](=[O:22])[CH2:20][N:8]3[CH2:9][CH2:10][C:2]4[C:3](=[N:4][CH:5]=[CH:6][N:1]=4)[CH2:7]3)[CH2:24][CH2:25]2)[CH2:32][CH2:31][CH2:30]1

Komponenten

7

Versuchsvorschrift

To a suspension of 5,6,7,8-tetrahydropyrido[3,4-b]pyrazine (70 mg, 0.518 mmol), NaI (50 mg, 0.333 mmol), and K2CO3 (200 mg, 1.45 mmol) in acetonitrile is added 2-chloro-1-(4-cyclobutyl-piperazin-1-yl)-ethanone (112 mg, 0.518 mmol). The mixture is stirred overnight at rt, diluted with DCM (20 mL) and filtered through Celite. The filtrate is evaporated and the crude product is purified by silica gel chromatography eluting with EtOAc/MeOH/NEt3 (95:5:5) to yield the title compound. 1H NMR (300 MHz, CDCl3) δ 8.35 (2H, dd), 3.85 (2H, s), 3.70-3.66 (m, 4H), 3.46 (2H, s), 3.09 (2H, t), 2.96 (2H, t), 2.75 (1H, m), 2.37-2.34 (4H, m), 2.09-1.67 (m, 6H); MS (+VE) m/z 316.21 (M++1).

Aufarbeitung

  1. filtrationfiltered through Celite
  2. customThe filtrate is evaporated
  3. customthe crude product is purified by silica gel chromatography
  4. washeluting with EtOAc/MeOH/NEt3 (95:5:5)

Quellen und Nachweise

ORD-Eintrag
ord-f8e9205dc2ce46b09e081bf008ee17d4
Quelldatensatz
uspto-grants-2010_09
Patentnummer
US07795262B2

Notizen zur Reaktion

Wird geladen…